NKI Scientists Receive Major Federal Grants for Alzheimer's Research
On September 12, New York State Senator David Carlucci visited NKI and toured the Center for Dementia Research (CDR). During the Senator's visit, NKI announced the awarding of several major federal research grants to CDR investigators, including a prestigious NIH Program Project Grant awarded to the CDR's Director, Ralph Nixon, PhD, MD. Dr. Nixon commented, "We are gratified that NIH places strong confidence in the AD research programs at the CDR and their promise for pioneering innovative, more effective therapies for AD and related dementias." Senator Carlucci's past appropriation of State funds for a state-of-the-art microscope helped NKI's scientists to secure the highly competitive federal grants.
Click here for the complete press release from the New York State Office of Mental Health.
Russell Tobe, M.D., Receives NAMI Rockland Award
NKI's Outpatient Research Department Director, Dr. Russell Tobe, was presented with the Florence Gould Gross Award to Friends of People with Mental Illness at NAMI Rockland's 2017 Awards Celebration and Dinner. Dr. Tobe was honored for his longstanding commitment to the community, and for his contributions in advocacy, education, and research. As a member of NAMI Rockland's Advisory Council, Dr. Tobe shares his expertise with families, teachers, and community members, and is always available to help those in need.
The Florence Gould Gross Award is named for NAMI Rockland's founding president, and recognizes people for their substantial contributions to improving the quality of life and advancing the cause of individuals and families impacted by mental illness.
Nixon Lab Findings Announced at the Alzheimer’s Association International Conference
New findings from the laboratory of Center for Dementia Research Director Dr. Ralph Nixon (in collaboration with EIP Pharma, LLC) were announced at the Alzheimer’s Association International Conference held recently in London. The investigators found that the EIP licensed investigational drug neflamapimod reversed a critical Alzheimer's-related physiologic defect in human patient cells cultured from individuals with a genetic defect predisposing them to early onset Alzheimer's disease. In their presentation, the authors concluded:
"The findings provide the first evidence that p38α antagonism could be a means to therapeutically target Alzheimer-related endosomal dysfunction. Further, the correlation between in vitro potency of neflamapimod on reversing endolysosomal dysfunction with clinical dose-response suggests that this pharmacological effect, rather than anti-inflammatory activity, may underlie the clinical activity of neflamapimod on episodic memory, noted in a recently concluded EIP phase 2a clinical trial in Alzheimer's patients."
For more details about this research, see the press release from EIP Pharma. Dr. Nixon recently published a review in the FASEB Journal on a key underlying physiological dysfunction in Alzheimer's disease.
OMH Clinical Laboratories Receive Accreditation from College of American Pathologists
The Accreditation Committee of the College of American Pathologists (CAP) has awarded accreditation to the OMH Clinical Laboratories located at the Nathan Kline Institute, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
The Laboratories Director, Timothy P. Hilbert, MD, PhD, JD, was advised of this national recognition and congratulated for the excellence of the services being provided. The OMH Clinical Laboratories at Nathan Kline Institute is one of more than 7,700 CAP-accredited facilities worldwide.
“The lab has been continuously accredited by CAP for almost 25 years. It’s a wonderful testament to the dedication of our staff and the exceptional quality of their work,” said Dr. Hilbert.
Director of the Nathan Kline Institute, Dr. Donald Goff, upon learning of the laboratory’s accreditation, commented, “Congratulations to Dr. Tim Hilbert and to the entire staff of the OMH Clinical Labs on this achievement. Maintaining the distinction of CAP accreditation is no small accomplishment and speaks to the professionalism and commitment to excellence the members of the lab demonstrate daily in support of the patients and mission of the OMH.”
The CAP Laboratory Accreditation Program was initiated in the early 1960s and is recognized by the U.S federal government as being equal-to or more-stringent-than the government’s own inspection program.
During the CAP accreditation process, which is designed to ensure the highest standard of care for all laboratory patients, inspectors examine the laboratory’s records and quality control of procedures for the preceding two years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and records, and overall management.
NKI Research Points to Link Between Diabetes and Alzheimer's
New research from the lab of Paul Mathews, PhD, part of NKI´s Center for Dementia Research, indicates a link between diabetes and Alzheimer´s disease. The study, which appears in the Journal of Neuroscience, examined the brains of diabetic monkeys and found insulin resistance and other changes consistent with early events in the brain that may predispose people to Alzheimer´s disease. This research was reported in Alzforum.
NKI Researcher Recognized with Alzheimer's Association Science Award
Ralph A. Nixon, MD, PhD, Director of the Center for Dementia Research at NKI and Professor of Psychiatry and Cell Biology at New York University Langone Medical Center, has been recognized by the Alzheimer´s Association with the Zaven Khachaturian Award for his achievement in advancing the field of Alzheimer´s disease science.
A press release from the Alzheimer´s Association notes that "Dr. Nixon´s pioneering research into the early brain changes associated with Alzheimer´s disease, including the abnormal breakdown of proteins, has helped scientists better understand the process by which Alzheimer´s develops and progresses. His research has helped identify new avenues for investigating potential Alzheimer´s disease therapies."